Program
lucoridalines
Also written as “DA-9701”, “DA-9701-R” and “Motilitone 30mg”.
Its studies are mostly in Dyspepsia, led by 2 companies.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Dong-A ST | 31 open or running | phase 4since Mar 19, 2013 | Mar 19, 2013 | Oct 2027phase 4 · NCT07686679 |
| Dong-A Pharmaceutical | 10 open or running | phase 4since Oct 26, 2012 | Oct 26, 2012 | none ahead |
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Oct 26, 2012First study: phase 4 study in Healthy Female and MaleNew to Dong-A PharmaceuticalDong-A Pharmaceutical · NCT01719575 · 30 enrolled · Korea, Republic of
- Mar 19, 2013Dong-A ST's first study: phase 4 study in Functional DyspepsiaNew to Dong-A STDong-A ST · NCT01817465 · 389 enrolled · Korea, Republic of
- Sep 5, 2014Phase 2 study in DyspepsiaDong-A ST · NCT02365701 · 45 enrolled · United States
- Jun 30, 2026Phase 4 study in Functional DyspepsiaDong-A ST · NCT07686679 · 300 planned · South Korea
Ahead
- Oct 2027Primary completion: phase 4 study in Functional DyspepsiaDong-A ST · NCT07686679
TargetBeta
Not stated by its company or a source we have read. Most early programs say nothing of it.
Studies
All 4 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Led by | Primary completion | Size |
|---|---|---|---|---|---|
| NCT07686679Functional Dyspepsia · South Korea | 4 | Recruiting | Dong-A ST | Oct 2027 | 300 |
| NCT02365701Dyspepsia · United States | 2 | Completed | Dong-A ST | Feb 2018 | 45 |
| NCT01817465Functional Dyspepsia · Korea, Republic of | 4 | Completed | Dong-A ST | Mar 2014 | 389 |
| NCT01719575Healthy Female and Male · Korea, Republic of | 4 | Completed | Dong-A Pharmaceutical | Nov 2012 | 30 |
How it is read
Names in the registry
- “DA-9701”, 1 entry
- “DA-9701-R”, 1 entry
- “Motilitone 30mg”, 1 entry
- “Motilitone ®”, 1 entry
- “Motilitone”, 1 entry
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.